A New Horizon
For patients with relapsed / refractory high-risk myelodysplastic syndromes
Gallop Oncology is a clinical-stage biotechnology company advancing a first-in-class, mutation-agnostic approach targeting galectin-9 to treat relapsed/refractory high-risk myelodysplastic syndromes (MDS)
Targeting the Biology that Drives MDS
LYT-200 is a monoclonal antibody against galectin-9, an important oncogenic driver and potent immunosuppressor. Its mutation-agnostic, dual mechanism of action targets both malignant cells and the immunosuppressive environment that sustains disease.
Phase 1b Data
LYT-200 has demonstrated compelling clinical efficacy and safety in a Phase 1b trial.